Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | F10 | P00742 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.45 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7682048 | 0.89 | KMT2A (0.57) | MEN1KMT2AKDM4EF10MAPT | |
| SCHEMBL7688134 | 0.88 | F10 (0.46) | MEN1KMT2AKDM4EF10NOD2 | |
| SCHEMBL6742117 | 0.85 | GAA (0.51) | KDM4EMAPTGAALTB4RLTB4R2 | |
| SCHEMBL8690101 | 0.81 | MEN1 (0.51) | MEN1KMT2AKDM4EF10MAPT | |
| SCHEMBL8694830 | 0.78 | MEN1 (0.69) | MEN1KMT2AKDM4EF10MAPT | |
| SCHEMBL7681737 | 0.78 | KDM4E (0.42) | MEN1KMT2AKDM4EF10MAPT | |
| SCHEMBL7684727 | 0.78 | F10 (0.46) | MEN1KMT2AKDM4EF10MAPT | |
| SCHEMBL10629278 | 0.77 | KMT2A (0.71) | MEN1KMT2AKDM4EF10NOD2 | |
| SCHEMBL7682421 | 0.77 | MTNR1A (0.51) | MEN1KMT2AKDM4EF10NOD2 | |
| SCHEMBL18733289 | 0.77 | F10 (0.52) | MEN1KMT2AF10MAPTLTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043995-A1 | Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them | BIGNON ERIC (FR) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043995-A1 | Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them | CCKAR, CCKBR, NPY1R | MEN1 2842/4885KMT2A 4045/4885KDM4E 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.